MultiPlan Corp.

As of September 4, 2025, MultiPlan Corp. shows a bullish technical trend, supported by a bullish weekly MACD and Bollinger Bands, despite some mixed signals from the KST and Dow Theory, while significantly outperforming the S&P 500 with a year-to-date return of 274.76%.

As of February 28, 2023, MultiPlan Corp. is considered a risky investment due to its overvaluation indicated by a high Price to Book Value of 95.80, a low ROE of -896.41%, and a P/E ratio of -15.00, despite a strong YTD return of 274.76 and recent volatility.

As of February 28, 2023, MultiPlan Corp. is considered overvalued with a risky valuation grade, reflected by a high Price to Book Value of 95.80, an EV to EBIT ratio of 76.24, and a troubling ROE of -896.41%, despite a strong year-to-date return of 180.72%.

As of June 17, 2025, the technical trend is bullish, supported by positive MACD and moving averages, although the weekly RSI shows some short-term weakness.

MultiPlan Corp. provides data analytics and cost management solutions for the healthcare industry, with recent net sales of $231 million and a net loss of $71 million. It has a market cap of approximately $1.44 billion and operates as a micro-cap company.

As of Jun 18, MultiPlan Corp. has a market capitalization of 1,444.25 million, with net sales of 927.46 million and a net profit of -1,177.47 million over the latest four quarters.